摘要
目的:探讨放射性核素骨显像与血清前列腺特异性抗原(PSA)联合检测在前列腺癌骨转移诊断中的临床意义。方法:对130例前列腺癌患者的PSA检测结果及SPECT骨显像进行回顾性分析。结果:130例前列腺癌患者,骨显像诊断骨转移86例,阳性率为66.2%。在86例骨转移的患者中,发生脊椎转移77例,占77.9%,骨盆转移65例,占75.6%,肋骨转移42例,占48.8%,肩胛骨转移11例,占12.8%,胸骨转移7例,占8.1%,颅骨转移6例,占7%。脊椎和骨盆是前列腺癌骨转移主要涉及的部位。骨显像阳性组和骨显像阴性组PSA均值差异有显著性(P<0.01),PSA<20μg/L的前列腺癌患者发生骨转移的可能性小,PSA≥20μg/L的患者发生骨转移的可能性大。结论:PSA≥20μg/L的前列腺患者应行放射性核素骨显像检查。放射性核素全身骨显像与血清PSA浓度联合检测对于前列腺癌骨转移的临床诊断具有重要的指导意义。
Objective：To probe the clinical significance of the combined detection of radionuelide bone imaging and plasma levels of prostate specific antigen （PSA） in patients with prostate cancer. Methods：To retrospectively analyze the levels of serum PSA and the findings of radionuclide bone imaging in 130 patients with prostate cancer. Results：Among 130 cases, 86 cases with bone metastases were found by radionuclide bone imaging, with the positive rate 66.2%. In the 86 cases, the tumor location included 77（79.9%） in the spime,66（75.6%） inthe pelvis, 42（48.8%） in the rib, 11（12.8%） in the seapnla, 7（8.1%） in the stemtion, and 6（7%） in the skuel and the spine and pelvis were mainly involved sites for bone metastases of prostate cancer. The value of PSA between positive group and negative group had significant difference （ P 〈 0.01）. Prostate cancer patients with PSA 〈 20μg/L had low morbidity for bone metastases. While for patients with PSA≥20μg/L, the morbidity for bone metastases was high. Concluslon：Radionuclide bone imaging should be performed in prostate cancer patients with PSA ≥ 20μg/L. The combined detection of radionuelide bone imaging and the serum PSA levels would play an important role in clinical diagnosis of bone metastases for patients with prostate cancer.
出处
《医学影像学杂志》
2007年第10期1024-1026,共3页
Journal of Medical Imaging
